Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|January 15, 2013
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trialIstvan Lang, Thomas Brodowicz, Larisa Ryvo, et al.
Wiener Medizinische Wochenschrift (1946)|March 20, 2013
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in AustriaEvelyne Bareck, Ahmed Ba-Ssalamah, Thomas Brodowicz, et al.
Anti-Cancer Drugs|March 27, 2014
Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomasKira Brämswig, Ferdinand Ploner, Alexandra Martel, et al.
The Lancet. Oncology|February 17, 2012
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 studyChandra P Belani, Thomas Brodowicz, Tudor E Ciuleanu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2018
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcomaThomas Brodowicz, Olivier Mir, Jennifer Wallet, et al.
Journal for Immunotherapy of Cancer|March 25, 2021
Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patientsAngelika M Starzer, Anna S Berghoff, Rainer Hamacher, et al.
Cancer|March 16, 2017
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysisVincent Berry, Laurent Basson, Emilie Bogart, et al.
Lung Cancer (Amsterdam, Netherlands)|March 30, 2006
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialThomas Brodowicz, Maciej Krzakowski, Matjaz Zwitter, et al.
The Lancet. Oncology|August 10, 2016
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trialChristoph Zielinski, István Láng, Moshe Inbar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trialChristoph Zielinski, Semir Beslija, Zrinka Mrsic-Krmpotic, et al.
Pageof 9